Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway

Table 1 Effect of Angelica Sinensis on viability of myotubes (%)

		Concentration of Angelica Sinensis treatment (ng/mL)
	Control	1	10	10²	10³	10⁴	10⁵	10⁶
24 h	100.00 ± 3.53	99.45 ± 4.09	99.89 ± 5.64	98.18 ± 4.52	93.94 ± 6.59	91.24 ± 4.34	83.62 ± 5.07*	74.41 ± 5.88*
48 h	100.00 ± 3.42	100.15 ± 5.34	100.04 ± 5.56	100.13 ± 5.75	93.49 ± 4.44	91.22 ± 4.09	75.08 ± 5.15*	68.82 ± 4.65*
72 h	100.00 ± 3.75	98.56 ± 3.49	99.42 ± 5.21	99.17 ± 4.86	91.31 ± 3.92	90.64 ± 3.59	74.93 ± 5.26*	68.45 ± 4.53*

Values are mean ± SD (n = 4). Data were analyzed with one-way ANOVA with dose factors. *Significantly different compared with the control at the same time of culture (Scheffe’s post hoc analysis, P < 0.05).

ISSN: 2662-7671